Martin MJ, Rome BN, Hwang CS, Lalani HS, Raymakers AJN, Rand LZG, Bendicksen L, Mooney H, Liu ITT, Avorn J, Kesselheim AS - National Academy for State Health Policy (NASHP)
- Policy Interactions
- Price, Value, and Access
Summary:
This white paper offers comprehensive guidance for state PDABs on conducting drug affordability reviews, covering how to define affordability across multiple perspectives and how to evaluate drug evidence, pricing and spending, comparative effectiveness, economic analyses, patient access, and market dynamics. It emphasizes the need for holistic, indication-specific assessments that account for statutory constraints, stakeholder engagement, and the complexities of the pharmaceutical supply chain.
VIEW SOURCE
Recent Work from PORTAL
Pharmaceutical Industry Pay-Per-Click Advertising Strategies to Influence Public Opinions on Drug Pricing
Eisenkraft Klein D, Kesselheim AS - Clinical Pharmacology & Therapeutics
- Research Publications
- Price, Value, and Access
Coverage and Costs for Medications After Medicare Price Negotiation
Cai CL, Bucha S, Kesselheim AS, Rome BN - Journal of General Internal Medicine
- Research Publications
- Price, Value, and Access
Methodological Divergence in Oncology HTA: Implications for International Harmonization and the Handling of Uncertainty
Chen NC, Bullement A, Zemplenyi AT, O'Bryant CL, Kaizer AM, Anderson KE, McQueen RB - PharmacoEconomics Open
- Research Publications
- Price, Value, and Access
Program On Regulation, Therapeutics, And Law (PORTAL)
Division of Pharmacoepidemiology and Pharmacoeconomics
Brigham and Women's Hospital • Harvard Medical School
41 Avenue Louis Pasteur, Suite 0B17, Boston, MA 02115
©2026 Program On Regulation, Therapeutics, And Law (PORTAL). All rights reserved.